RARE Quote, Financials, Valuation and Earnings

Amicus Therapeutics, Inc. has a net margin of -112.81% compared to Ultragenyx Pharmaceutical, Inc.'s net margin of 10.24%. Ultragenyx Pharmaceutical, Inc.'s return on equity of -307.83% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.

Ultragenyx Pharmaceutical, Inc. has a consensus price target of $81.85, signalling upside risk potential of 135.54%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $15.25 which suggests that it could grow by 7.32%. Given that Ultragenyx Pharmaceutical, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Ultragenyx Pharmaceutical, Inc. is more attractive than Amicus Therapeutics, Inc..

Ultragenyx Pharmaceutical, Inc. has a beta of 0.162, which suggesting that the stock is 83.763% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.463, suggesting its less volatile than the S&P 500 by 53.675%.

Ultragenyx Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ultragenyx Pharmaceutical, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Ultragenyx Pharmaceutical, Inc. quarterly revenues are $159.9M, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Ultragenyx Pharmaceutical, Inc.'s net income of -$180.4M is lower than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Ultragenyx Pharmaceutical, Inc.'s price-to-earnings ratio is -- while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical, Inc. is 5.38x versus 7.27x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Geron Corp. has a net margin of -112.81% compared to Ultragenyx Pharmaceutical, Inc.'s net margin of -39.02%. Ultragenyx Pharmaceutical, Inc.'s return on equity of -307.83% beat Geron Corp.'s return on equity of -29.65%.

Ultragenyx Pharmaceutical, Inc. has a consensus price target of $81.85, signalling upside risk potential of 135.54%. On the other hand Geron Corp. has an analysts' consensus of $3.60 which suggests that it could grow by 166.67%. Given that Geron Corp. has higher upside potential than Ultragenyx Pharmaceutical, Inc., analysts believe Geron Corp. is more attractive than Ultragenyx Pharmaceutical, Inc..

Ultragenyx Pharmaceutical, Inc. has a beta of 0.162, which suggesting that the stock is 83.763% less volatile than S&P 500. In comparison Geron Corp. has a beta of 0.567, suggesting its less volatile than the S&P 500 by 43.26%.

Ultragenyx Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geron Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ultragenyx Pharmaceutical, Inc. pays -- of its earnings as a dividend. Geron Corp. pays out -- of its earnings as a dividend.

Ultragenyx Pharmaceutical, Inc. quarterly revenues are $159.9M, which are larger than Geron Corp. quarterly revenues of $47.2M. Ultragenyx Pharmaceutical, Inc.'s net income of -$180.4M is lower than Geron Corp.'s net income of -$18.4M. Notably, Ultragenyx Pharmaceutical, Inc.'s price-to-earnings ratio is -- while Geron Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical, Inc. is 5.38x versus 4.90x for Geron Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -112.81% compared to Ultragenyx Pharmaceutical, Inc.'s net margin of 38.89%. Ultragenyx Pharmaceutical, Inc.'s return on equity of -307.83% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

Ultragenyx Pharmaceutical, Inc. has a consensus price target of $81.85, signalling upside risk potential of 135.54%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $789.90 which suggests that it could grow by 1.35%. Given that Ultragenyx Pharmaceutical, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Ultragenyx Pharmaceutical, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

Ultragenyx Pharmaceutical, Inc. has a beta of 0.162, which suggesting that the stock is 83.763% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.

Ultragenyx Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.45% to investors and pays a quarterly dividend of $0.88 per share. Ultragenyx Pharmaceutical, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Ultragenyx Pharmaceutical, Inc. quarterly revenues are $159.9M, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Ultragenyx Pharmaceutical, Inc.'s net income of -$180.4M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Ultragenyx Pharmaceutical, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical, Inc. is 5.38x versus 6.03x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals, Inc. has a net margin of -112.81% compared to Ultragenyx Pharmaceutical, Inc.'s net margin of 34.76%. Ultragenyx Pharmaceutical, Inc.'s return on equity of -307.83% beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.13%.

Ultragenyx Pharmaceutical, Inc. has a consensus price target of $81.85, signalling upside risk potential of 135.54%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $489.04 which suggests that it could grow by 6.24%. Given that Ultragenyx Pharmaceutical, Inc. has higher upside potential than Vertex Pharmaceuticals, Inc., analysts believe Ultragenyx Pharmaceutical, Inc. is more attractive than Vertex Pharmaceuticals, Inc..

Ultragenyx Pharmaceutical, Inc. has a beta of 0.162, which suggesting that the stock is 83.763% less volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.249%.

Ultragenyx Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ultragenyx Pharmaceutical, Inc. pays -- of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Ultragenyx Pharmaceutical, Inc. quarterly revenues are $159.9M, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.1B. Ultragenyx Pharmaceutical, Inc.'s net income of -$180.4M is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.1B. Notably, Ultragenyx Pharmaceutical, Inc.'s price-to-earnings ratio is -- while Vertex Pharmaceuticals, Inc.'s PE ratio is 32.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical, Inc. is 5.38x versus 10.16x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.